We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Raman Imaging Probes for Detecting Enzyme Activities Could Aid Disease Diagnosis

By LabMedica International staff writers
Posted on 02 Jun 2023
Print article
Image: Highly sensitive Raman probe detects enzyme expression in heterogeneous tissues (Photo courtesy of Tokyo Tech)
Image: Highly sensitive Raman probe detects enzyme expression in heterogeneous tissues (Photo courtesy of Tokyo Tech)

Enzymes play a crucial role in various biological processes, which makes them suitable biomarkers for disease detection. For instance, cancer diagnosis often uses fluorescence imaging to identify cancer-related enzymes that have multiplied in cells affected by the disease. Given the heterogeneous nature of tumor tissues, being able to detect multiple enzyme activities at once could enhance the precision of cancer visualization and diagnosis. However, detecting multiple enzyme activities using fluorescence imaging can be challenging in heterogeneous tumor tissues and other complex biological phenomena. Raman spectral imaging, with its narrower spectral width, provides a promising alternative for multiplex biological imaging with molecular probes. Over time, a number of functional and activatable Raman probes (dyes) have been developed for bioanalyte detection, but their use for enzyme activity detection has been limited. In addition, prior design strategies have been unsuccessful in controlling the diffusion of enzyme-generated hydrolysis product of these probes, making it difficult to identify areas with targeted enzyme activity in tissues.

Now, a team of researchers led by Tokyo Institute of Technology (Tokyo Tech, Tokyo, Japan) has come up with a novel molecular design approach, taking cues from aggregation-based fluorescent probes. The team has developed activatable Raman probes based on 9CN-rhodol using a novel mechanism for Raman signal activation. The researchers have shown that Raman imaging has more potential for detecting multiple enzyme activities compared to fluorescence imaging. This innovative strategy allows the creation of highly activatable Raman probes that possess strong aggregation and multiplexing ability, providing a promising tool for expanding the range of Raman probes that can detect multiple enzyme activities in heterogeneous biological tissues.

The researchers first synthesized 9CN-rhodol derivatives and chose two, 9CN-JR and 9CN-JCR, to design the activatable Raman probes. They tested the enzyme detection capabilities of both probes in live cells, using a dual-color stimulated Raman scattering (SRS) imaging technique. Among the two, 9CN-JCR outperformed and proved to be the more effective probe for multiplexing. The team then isotope-labeled the nitril group of 9CN-JCR scaffold with Carbon-13 (13C) and Nitrogen-15 (15N), and developed two new isotope edited 9CN-JCR probes for γ-glutamyl transpeptidase and dipeptidyl peptidase-4 enzymes. These 9CN-JCR-based probes successfully detected all enzyme activities simultaneously in the live cell culture.

Additionally, the probes enabled ex vivo imaging of specific cell areas showing targeted enzyme activity in Drosophila wing disk and fat body. The high spatial selectivity and sensitivity exhibited by the 9CN-JCR probes were attributed to the electronic pre-resonance effect of the scaffold dye and aggregate formation of the hydrolysis products formed by probe-cell interaction. These rhodol-based probes could aggregate when reacting with enzymes, which enhanced their intracellular retention and boosted the SRS signal intensity during enzyme detection. Overall, the approach presented in this study could support the development of highly specific activatable Raman probes for simultaneous detection of multiple enzyme activities.

"Our aggregation-based molecular design strategy for Raman probes will offer substantial advantages for applications involving the investigation of enzyme activity associated with diseases and essential biological activities," said Professor Mako Kamiya of Tokyo Tech who led the research.

Related Links:
Tokyo Tech 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.